Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06276504
Other study ID # APHP211001
Secondary ID 2023-503520-31-0
Status Not yet recruiting
Phase Phase 2/Phase 3
First received
Last updated
Start date April 2024
Est. completion date April 2028

Study information

Verified date February 2024
Source Assistance Publique - Hôpitaux de Paris
Contact Valérie POURCHER, Pr
Phone +33 (0)1 42 16 02 62
Email valerie.martinez@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to assess the efficacy and safety of pembrolizumab in immunocompromised patients with progressive multifocal leukoencephalopathy (PML). This phase II, multicenter, single-arm study includes patients with an underlying cause of immunosuppression hardly reversible, i.e. not the patients with HIV nor those receiving biologics for chronic inflammatory diseases. Patients will receive intravenous pembrolizumab (2 mg/kg, maximum 200 mg) at month 0, 1 and 2 (total of three doses). The primary endpoint will be achieving at least one negative result of JCV viral load in cerebrospinal fluid (CSF) within the M0 to M3 period.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 33
Est. completion date April 2028
Est. primary completion date April 2028
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age = 18 years old 2. Diagnosis of definite PML since less than 2 months according to American Academy of Neurology 3. Presence of JCV in the CSF in the last CSF sampling. 4. Signed informed consent (from the patient, or if unable to consent, from a surrogate) 5. For women of childbearing potential: negative serum or urine b-HCG test and agree to use a highly effective contraception methods during 8 months (i.e. until 6 months after end of experimental treatment) Exclusion Criteria: 1. Patients in whom immune reconstitution is achievable (HIV infection - Multiple sclerosis - Auto-immune and inflammatory diseases) 2. Patients who have received solid organ transplantation 3. Hypersensitivity to the active substance or to any of the excipients 4. Life expectancy less than 1 month 5. Pregnancy or lactating women or planning birth during the study period 6. Having previously been treated by anti-PD1mAb 7. Patient receiving IL-2 or IL-7 for the treatment of PML at inclusion 8. Patient whose weight is > 100kg 9. Participation in other interventional study [a patient already included in another interventional study for which the treatment can lead to an immunodepression can be included if: - the investigational treatment has been completed and there is no risk of drug interaction with the administration of Pembrolizumab as defined in PENALTY study - if this does not alter the study's ability to evaluate the effect of Pembrolizumab in terms of safety and efficacy (from the investigator's point of view)] 10. Patient without national health insurance, and patient on AME (state medical aid) 11. Patient under guardianship or curatorship 12. Patient deprived of their liberty by a judicial or administrative decision

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Pembrolizumab, 25 mg/ml solution for intravenous (IV) injection
Pembrolizumab administration at D0, M1 and M2

Locations

Country Name City State
France Hôpital Pitié-Salpêtrière - Médecine Intensive Réanimation Paris
France Hôpital Pitié-Salpêtrière - Service d'hématologie clinique Paris
France Hôpital Pitié-Salpêtrière - Service des Maladies infectieuses et tropicales Paris

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Negativation of JCV viral load in the CSF as assessed by PCR: at least one JCV PCR in the CSF negative in the Day 0 to Month 3 period At baseline (Day 0), 1 month, 2 months and 3 months
Secondary Negativation of JCV PCR viral load in the CSF: cumulative incidence of negative JCV viral load measures by PCR in CSF, with death as competing event At baseline (Day 0), 1 month, 2 months and 3 months
Secondary Evolution of the JCV viral load in the CSF (repeated measures JCV PCR in CSF) At baseline (Day 0), 1 month, 2 months and 3 months
Secondary Repositivation of JCV PCR: at least a positive result following at least a negative result At baseline (Day 0), 1 month, 2 months and 3 months
Secondary Evolution of National Institutes of Health Stroke Scale (NIHSS) score Repeated measures of neurological status At baseline (Day 0), 1 month, 2 months, 3 months, 6 months, and 12 months
Secondary Evolution of 6-item Modified Rankin Scale score (includes death as most severe state) Repeated measures of degree of disability or dependence in the daily activities in neurological conditions At baseline (Day 0), 1 month, 2 months, 3 months, 6 months, and 12 months
Secondary Evolution of Glasgow Outcome Scale Extended (GOS-E) score Repeated measures of neurological outcome and degree of disability in neurological conditions At baseline (Day 0), 1 month, 2 months, 3 months, 6 months, and 12 months
Secondary Relapse or progression Adjudication by a dedicated committee ; based on clinical evolution, JCV PCR in CSF, brain MRI From baseline to end of participation, a maximum of 12 months
Secondary Death (and date of death) From baseline to end of participation, a maximum of 12 months
Secondary Cause specific death: death related to PML Adjudication by a dedicated committee From baseline to end of participation, a maximum of 12 months
Secondary Any adverse event classified by using US NCI CTCAE From baseline to end of participation, a maximum of 12 months
See also
  Status Clinical Trial Phase
Terminated NCT01211639 - Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy N/A
Completed NCT02004444 - JC Virus Reactivation in Multiple Sclerosis N/A
Recruiting NCT05849467 - Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy Phase 1
Recruiting NCT01730131 - Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
Recruiting NCT04781309 - NT-I7, a Long-Acting Recombinant IL-7 Molecule, as an Immune Reconstitution Strategy for Lymphopenia in Patients With Progressive Multifocal Leukoencephalopathy Early Phase 1
Completed NCT02694783 - Adoptive Cellular Immunotherapy for Progressive Multifocal Leukoencephalopathy With Ex Vivo Generated Polyomavirus-Specific T-Cells Early Phase 1
Completed NCT01132053 - Role of Inflammation in Progressive Multifocal Leukoencephalopathy (PML)
Completed NCT03399981 - Tysabri Observational Cohort Study - Multiple Sclerosis (MS) Registries
Terminated NCT00746941 - Study to Explore the Effect of Mefloquine in Participants With Progressive Multifocal Leukoencephalopathy (PML) Phase 1/Phase 2
Completed NCT02895581 - Retrospective Study of the Survival of Patients Suffering From Hiv-related Progressive Multifocal Leukoencephalopathy N/A
Recruiting NCT04453917 - Dynamics of T Cell Expression of Immune Checkpoint Molecules in Progressive Multifocal Leukoencephalopathy N/A
Not yet recruiting NCT05541549 - A Phase 2 Study Evaluating JCPyV-specific T Cell Therapy for PML Phase 2
Recruiting NCT04091932 - Treatment of PD-1 Inhibitor in AIDS-associated PML Phase 2